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Characterization of anti-leukemia 
components from Indigo naturalis 
using comprehensive two-
dimensional K562/cell membrane 
chromatography and in silico target 
identification
Xunxun Wu1,2,*, Xiaofei Chen2,*, Jia Dan2, Yan Cao2, Shouhong Gao2, Zhiying Guo1,2, 
Philipp Zerbe3, Yifeng Chai2, Yong Diao1 & Lei Zhang2
Traditional Chinese Medicine (TCM) has been developed for thousands of years and has formed 
an integrated theoretical system based on a large amount of clinical practice. However, essential 
ingredients in TCM herbs have not been fully identified, and their precise mechanisms and targets are 
not elucidated. In this study, a new strategy combining comprehensive two-dimensional K562/cell 
membrane chromatographic system and in silico target identification was established to characterize 
active components from Indigo naturalis, a famous TCM herb that has been widely used for the 
treatment of leukemia in China, and their targets. Three active components, indirubin, tryptanthrin 
and isorhamnetin, were successfully characterized and their anti-leukemia effects were validated 
by cell viability and cell apoptosis assays. Isorhamnetin, with undefined cancer related targets, was 
selected for in silico target identification. Proto-oncogene tyrosine-protein kinase (Src) was identified 
as its membrane target and the dissociation constant (Kd) between Src and isorhamnetin was 3.81 μM. 
Furthermore, anti-leukemia effects of isorhamnetin were mediated by Src through inducing G2/M cell 
cycle arrest. The results demonstrated that the integrated strategy could efficiently characterize active 
components in TCM and their targets, which may bring a new light for a better understanding of the 
complex mechanism of herbal medicines.
Traditional Chinese Medicine (TCM), a complete system of healing developed in ancient China, is receiving more 
and more attention in China and throughout the world in recent decades1,2. However, the essential ingredients in 
TCM herbs have not been clearly identified and their precise mechanisms and targets have yet to be discovered, 
which seriously delays its integration into the modern health-care system3,4. How to characterize the active ingre-
dients in TCM and their molecular targets is still the most challenging task at present5,6. Thus, the development of 
a new strategy is extremely critical to screen active ingredients and elucidate drug-target interactions7.
Traditionally, the components in TCM formulae were separated and identified by phytochemical methods, 
and evaluated by pharmacological assays for their molecular targets and mechanism, but the processes were 
incomprehensive, time-consuming and also inefficient8. In recent years, cell membrane chromatography (CMC) 
has been extensively used for active component screening and identification based on the interactions between 
membrane receptors and active ingredients9–11. It combines the advantages of both biomaterials and classic chro-
matography and realizes online and high-throughput screening of potential active ingredients from complicated 
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biological samples12. In our previous study, a comprehensive two-dimensional (2D) high throughput screening 
system was firstly established which have successfully screened several active components from TCM herbs8,13. 
This biological chromatographic technique has been proven to be a powerful approach to screening active com-
ponents from TCM.
In silico target identification, also known as reverse screening, is a technique that can be used to fast identify 
potential targets of small molecules and construct drug-target networks14. This approach has been successfully 
used to identify new potential biological targets for known compounds, and targets for compounds among a 
family of related receptors15–17. In recent years, a large number of computational target fishing methods and data 
bases have been developed18,19. In light of the existing huge amounts of components in TCM and their complex 
targets, this method may be a preferred strategy to explore the ingredient-target interaction and the functional 
mechanism underlying the multi-component combinations at the molecular level.
In this study, a new strategy that combines the comprehensive 2D K562/CMC system and in silico target iden-
tification has been developed to characterize active components and their targets in Indigo naturalis (Qingdai), an 
important TCM herb that has been used in several effective formulae for leukemia20,21. As shown in Fig. 1, a com-
prehensive 2D K562/CMC system was first established for screening potential active components from Qingdai. 
Then, the anti-leukemia effects of the screened components were verified by cell viability and apoptosis assays. 
Next, in silico target identification methods were employed for target screening. Compound-receptor interactions 
were further confirmed by molecular docking, CMC competitive displacement assays, kinase inhibition assays 
and surface plasmon resonance (SPR) analysis. Furthermore, receptor mediated molecular mechanism of K562 
cell cycle regulation was analyzed. This novel methodology and strategy may provide a new way for characterizing 
active components from TCM and other complex systems and their targets.
Results
Identification of active components by comprehensive 2D K562/CMC system. A comprehensive 
two-dimensional K562/CMC system was first established based on our previous study8,13 (Fig. 2a,b). Two stand-
ard drugs, dexamethasone (binding to intracellular glucocorticoid receptor) and imatinib (acting on membrane 
receptor c-Kit and PDGFR) were selected to demonstrate the feasibility and selectivity of the proposed 2D K562/
CMC system. The three-dimensional (3D) plot of mixed standards was shown in Fig. 2c. As expected, dexametha-
sone has minor retention behavior on K562/CMC system, while imatinib has a significant retention characteristic 
on the K562/CMC model.
Then, the comprehensive 2D K562/CMC system was used to screen anti-leukemia components from Qingdai 
extracts. As shown in Fig. 2d and Table 1, four membrane affinity components from Qingdai were identified 
according to our comprehensive identification of the 24 chemical components by quadruple-time-of-flight mass 
spectrometry (Q-TOFMS) (Supplementary Table S1). Then, a simultaneous quantitative determination of these 
four components was conducted in Qingdai. The contents of indigo, indirubin, tryptanthrin and isorhamnetin 
were 138.1 mg/g, 37.0 mg/g, 7.2 mg/g and 4.0 mg/g crude drug, respectively. At formula weight m/z 263.0813, 
Figure 1. The flow diagram of characterizing anti-leukemia components and their targets from Indigo 
naturalis by the combination of comprehensive 2D K562/cell membrane chromatographic system and  
in silico target identification. 
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there appeared two retention components (Fig. 2d). According to our previous results, one might be indigo, and 
the other might be indirubin. To further confirm our assumption, mixed standards of indirubin and indigo were 
selected for K562/CMC analysis (Supplementary Fig. S1). The results showed that the retention time of indigo on 
the 1st dimension K562/CMC column was 2.5–7.5 min, while that of indirubin was 22.5–37.5 min. Thus, the three 
significant retention constituents were identified as indirubin, tryptanthrin and isorhamnetin, and the minor 
retention constituent was identified as indigo (Fig. 2e).
Figure 2. Construction and application of the proposed comprehensive 2D K562/CMC system Scheme of 
the 2D K562/CMC system. (a) K562/CMC column was equilibrated, and the 1st fraction was collected in pre-
column 1. (b) The 1st fraction was analyzed by a C18 column coupled with TOFMS while the 2nd fraction was 
collected in pre-column 2, then into the C18 column and TOFMS for analysis, alternately. (c) 3D plot of mixed 
standards obtained by 2D K562/CMC system. Dexamethasone was used as negative control, and showed no 
retention behavior on K562/CMC. Imatinib was used as positive control, and showed a significant retention 
characteristic on the K562/CMC. (d) 3D plot of Qingdai extracts obtained by 2D K562/CMC system. Three 
significant retention constituents were identified as indirubin, tryptanthrin and isorhamnetin, and one minor 
retention constituent was identified as indigo. (e) Chemical structures of potential bioactive components 
screened in Qingdai extracts.
Identification tR(1st K562/CMC, min) tR(2nd RPLC, min) Fomula Selected ion Expected Detected Error (ppm) Abund match(%)
indigo 2.5–7.5 9.47 C16H10N2O2 [M+ H]+ 263.0815 263.0813 0.76 98.98
indirubin 22.5–37.5 9.47 C16H10N2O2 [M+ H]+ 263.0815 263.0813 0.76 98.98
tryptanthrine 2.5–30 8.18 C15H8N2O2 [M+ H]+ 249.0659 249.0664 − 2.06 99.53
isorhamnetin 5–27.5 9.35 C16H12O7 [M+ H]+ 317.0656 317.0655 0.3 98.26
Table 1.  Retention components identified by TOFMS.
www.nature.com/scientificreports/
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Anti-leukemia effects validated by cell viability and cell apoptosis assays. In order to confirm the 
potential active components identified by the comprehensive 2D K562/CMC system, cell viability and cell apop-
tosis assays were adopted. The cell viability results of indirubin showed that the anti-leukemia effects occurred at 
a relative high concentration (100–200 μ M) (Supplementary Fig. S2). To be noted, because of its poor solubility in 
cell culture media, a large amount of this compound would be dissolved out22, the accurate anti-leukemia results 
of indirubin could not be achieved by cell viability assays in vitro. As for the other two components, isorhamnetin 
(Fig. 3) and tryptanthrin (Supplementary Fig. S3), they could also inhibit cell viability and induce apoptosis on 
K562 cells in a dose-dependent manner.
Target identification for isorhamnetin. In this study, PharmMapper Server (http://lilab.ecust.edu.cn/
pharmmapper/)23 and TargetHunter (http://www.cbligand.org/TargetHunter/)24 tools were selected for potential 
drug target identification. PharmMapper server is a spatial arrangement of features essential for a molecule to 
interact with a specific target receptor using pharmacophore mapping approach. By contrast, TargetHunter is 
built on biologically annotated chemical genomic (chemogenomic) databases with millions of bioactivity records, 
such as the ChEMBL database. These two methods, which based on different principles, are combinedly used in 
this study. Firstly, these two different tools are used for target screening (results shown in Supplementary Table S2 
and Table S3). Then, the common targets obtained by these two methods were analyzed via Venny analysis (http://
bioinfogp.cnb.csic.es/tools/venny/) (Supplementary Fig. S4). The receptors were ranked by fit score (Table 2). 
Estradiol 17-beta-dehydrogenase 1 is an enzyme that participates in androgen and estrogen metabolism, which 
seems to have no direct relation with leukemia. Aldose reductase is a cytosolic NADPH-dependent oxidoreduc-
tase that participates in glucose metabolism. It might be a receptor for isorhamnetin, but it didn’t appear at the 
cell membrane. However, Src is a non-receptor protein tyrosine kinase and could strongly interact with cellular 
membranes via an amino-terminal hydrophobic domain. The apparent Kd for binding of Src to the phosphati-
dyicholine/phosphatidylserine bilayer is 6 × 10−7 M24,25. This interaction is sufficiently strong to account for Src 
membrane targeting25,26. It is also a very important therapeutic target for leukemia in clinical practice, such as 
dasatinib, a widely used drug targeting at Src27. Thus, Src was selected for further validation.
Validation of isorhamnetin binding to Src. In silico target identification results suggested that Src 
kinase might be a receptor of isorhamnetin. To further validate that isorhamnetin could strongly interact with 
Src kinase on cellular membrane, different methods were selected to verify the interaction. Firstly, molecular 
docking study28 was selected and results showed that isorhamnetin was able to form three hydrogen bonds with 
the so-called hinge region, the sequence segment that connects the N-lobe to the C-lobe of the kinase domain 
(Fig. 4a). Hydrogen bonding with the hinge region is one feature of type I kinase inhibitors. The core rings of 
both compounds are further involved into a lipophilic sandwich interaction between Leu273, Val281, Ala293 
Figure 3. Cell vitality and apoptosis induced by isorhamnetin. (a) Effect of isorhamnetin on cell viability 
in K562 cells measured by CCK-8 assay after exposed to increased concentrations (0–200 μ M) for 48 h. (b) 
and (c) Cell apoptosis of isorhamnetin on K562 cells measured by Annexin V-FITC assay after exposed to 
increased concentrations (0–50 μ M) for 48 h. All data were shown as mean standard deviation (n = 6). Statistical 
significance was calculated by Student’s t-test.
www.nature.com/scientificreports/
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and Tyr340 on one side, and Leu393 on the other side of the catalytic cleft. Notably, the binding of isorhamnetin 
extends into the back pocket of the ATP-site with its methoxyphenyl motif in an orientation that is very similar to 
bosutinib, and it forms one additional hydrogen bond with the catalytic important Glu310 by the hydroxyl group.
Next, several K562/CMC columns were randomly selected and the existence of Src on cell membrane was 
verified by western-blotting assay (Fig. 4b). CMC competitive displacement assay was adopted using an existing 
Src ligand, dasatinib. Firstly, different concentrations of isorhamnetin (0 μ mol/L, 0.5 μ mol/L, 1 μ mol/L, 2 μ mol/L, 
5 μ mol/L, respectively) were added to the mobile phase as a competitor. The retention time of dasatinib decreased 
in the K562/CMC model with an increasing isorhamnetin concentration (Fig. 4b). This result indicated that 
dasatinib competed with the same receptor with isorhamnetin.
Rank PDB ID Target Name Number of Feature Fit Score Normalized Fit Score z’-score
5 1i5r Estradiol 17-beta-dehydrogenase 1 16 4.64 0.29 1.603
10 2dux Aldose reductase 12 4.441 0.3701 0.917026
11 2bdj Proto-oncogene tyrosine-protein kinase Src 6 4.413 0.7354 2.79099
51 1r1h Neprilysin 10 3.889 0.3889 − 0.495387
73 1l0g Beta-lactamase 9 3.795 0.4216 − 0.250371
133 2p4j Beta-secretase 1 13 3.687 0.2836 − 0.430497
189 1pl6 Sorbitol dehydrogenase 5 3.611 0.7222 − 0.617597
212 1v3i Beta-amylase 8 3.585 0.4481 − 0.715818
Table 2.  Eight common targets obtained by PharmMapper server and TargetHunter ranked by fit score 
according to PharmMapper server docking results.
Figure 4. Validation of isorhamnetin binding to Src kinase (a) Isorhamnetin docked in the ATP binding site 
of the human Src kinase domain. Relevant hydrogen bonds are shown in blue dashed lines. (b) Left panel: 
Chromatogram of dasatinib (10 mM, 5 μ L) on the K562/CMC system using 10 mM ammonium acetate buffer as 
the mobile phase. Mobile phases were added with (1) 0 μ mol/L; (2) 0.5 μ mol/L; (3) 1 μ mol/L ; (4) 2 μ mol/L;  
(5) 5 μ mol/L isorhamnetin, respectively. Right panel: Competitive displacement assay of isorhamnetin on 
K562/CMC columns (presented as k values) with different isorhamnetin concentrations (0, 0.5, 1, 2, and 5 μ M) 
added to the mobile phase. Protein levels of Src proteins in K562/CMC columns (C1, C2 and C3) and whole 
cells (W). (c) Selective ATP-competitive kinase assay of isorhamnetin through caliper mobility shift assay. 
(d) Representative example of isorhamnetin binding to Src kinase by SPR. Immobilized on Series S sensor 
chip CM5, and then the indicated concentrations of isorhamnetin were injected over the chip to obtain the 
sensorgrams. The 1:1 binding fitting model was used to determine the kinetic parameters. Error bars represent 
the standard deviation based on three independent samples (n = 3).
www.nature.com/scientificreports/
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In order to test the effect of isorhamnetin on the activity of Src kinase, the in vitro kinase inhibitory assay was 
performed29. The results showed that the IC50 of isorhamnetin was 6.9 μ M (Fig. 4c). SPR analysis was selected to 
further test the direct binding of isorhamnetin to Src. The results showed that the Kd between isorhamnetin and 
Src was 3.81 μ M (Fig. 4d).
Anti-leukemia mechanism of isorhamnetin. To further understand the underlying mechanisms of the 
anti- leukemia effects of isorhamnetin, its influence on K562 cell cycle was then analyzed. The data indicated 
that during the 24 h time period, isorhamnetin increased the percentage of G2/M phases in a dose-dependent 
manner (Fig. 5a). Then, the cell cycle checkpoint proteins were analyzed by western-blotting assay. The results 
demonstrated that the Src relevant pathway molecules such as pSrc, CDK1, Cyclin B1 were down-regulated, while 
ATR, Wee1 were up-regulated by isorhamnetin with a dose-dependent manner (Fig. 5b). To further verify that 
the effects on cell cycle regulation of isorhamnetin were through ATR, caffeine (an ATR inhibitor) was used to 
treat K562 cells for 0 h, 1 h, 3 h, 6 h and 12 h. The results demonstrated caffeine could almost completely neutralize 
the effects of isorhamnetin (Supplementary Fig. S5). These results demonstrated that isorhamnetin-induced cell 
cycle arrest was partly through Src/ATR/Wee 1/Cyclin B1/CDK1 pathway.
Figure 5. Isorhamnetin arrests K562 cells at G2/M phase via Src. (a) The effects of isorhamnetin on cell-cycle 
progression determined by flow cytometry. Representative cell-cycle distributions after exposure to 0, 12.5, 25 
and 50 μ M isorhamnetin for 24 h. (b) Western blotting analysis of whole cell extracts of K562 cells treated for 
24 hours with different doses of isorhamnetin, showing the dose-dependent down-regulation of pSrc416, CDK1, 
Cyclin B1 and up-regulation of ATR and Wee 1. pSrc416 indicates the phosphoryl-specific antibody targeting 
activated Src phosphorylated at Y416. (c) K562 cells were transfected with Src siRNA or negative control siRNA 
for 48 hours, then K562 cells were treated with different doses of isorhamnetin. Western blotting analysis of 
whole cell extracts showed the dose-dependent down-regulation of Cyclin B1 and CDK1 in negative control 
group. These two proteins displayed no remarkable change in Src siRNA group. (d) The K562 cells were pre-
treated with 8 nM dasatinib (the first line is control) for 12 h, then the K562 cells were treated with different 
doses of isorhamnetin for 24 h. The protein levels are shown in the above picture. (The typical full blot of the 
western blot is shown in Supplementary material).
www.nature.com/scientificreports/
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In order to demonstrate that the cell cycle arrest at G2/M phase induced by isorhamnetin was directly through 
Src, the Src receptor was knocked down by Src siRNA or the phosphorylation state of Src was suppressed by 
dasatinib. Firstly, the most effective siRNA and suitable concentration of dasatinib were screened. According to 
the screened results (Supplementary Figs S6 and S8 and Table S4), Src siRNA-2, negative control (NC) siRNA 
and dasatinib at 8 nM were selected for further study. Then, the cell cycle was assayed by flow cytometry and 
the cell cycle checkpoint related proteins were analyzed by western blotting assays. After the Src receptor was 
knocked down, isorhamnetin could not arrest cell cycle at G2/M phase anymore in a dose-dependent man-
ner (Supplementary Fig. S7). It had minor effects or even no effect on cell cycle regulation. According to the 
western-blotting results, transfection of K562 cells with Src siRNA also reversed the isorhamnetin inhibition of 
Cyclin B1 and CDK1 activation seen in cells transfected with the NC siRNA (Fig. 5c), indicating that activation 
of the Cyclin B1 and CDK1 pathways were in part regulated by Src in K562 cells. In addition, after the phospho-
rylation state of Src416 was suppressed by dasatinib, the cell cycle regulation effects of isorhamnetin have also been 
arrested (Supplementary Fig. S9). The western-blotting results showed that the protein levels of Wee 1, Cyclin 
B1 and CDK1 had no significant difference after treatment of isorhamnetin at different concentrations (Fig. 5d), 
indicating that the regulation of the Wee 1, Cyclin B1 and CDK1 pathways was in part through the phosphoryl-
ation of Src416.
Discussion
In view of the vast amounts of TCM formulae and components, only a small portion of active components 
and targets have been validated before. The lack of efficient strategies and methodologies limits the moderni-
zation of TCM. On the basis of our prior research, an integrated strategy was established for the characteriza-
tion of anti-leukemia components from Indigo naturalis using comprehensive 2D K562/CMC and in silico target 
identification.
CMC is an affinity chromatography technology which is based on the interaction between active components 
and membrane receptors. It has been widely used for screening and identification of active molecules in complex 
samples. The advantage of CMC is that it is widely applicable to any complex samples including TCM herbs with-
out requiring isolation or purification of individual small molecules. Moreover, the method is a comprehensive 
and efficient approach for active ingredient screening and identification. The cell membranes can be obtained 
from any cells or tissues in physiological or pathological states. When identifying a specific target-binding mol-
ecule, an overexpression or reduced expression state membrane receptor can also be used30,31. In our previous 
study, a novel comprehensive 2D CMC system was established8 and several active components were successfully 
identified via that system. In this study, a sensitive comprehensive 2D K562/CMC system combined with opti-
mized stable columns9 was first established for rapid screening and characterization of potential active compo-
nents from Qingdai. In comparison with the previous CMC online systems, the optimized columns were first 
applied to the comprehensive 2D K562/CMC system and two pre-columns were adopted to improve the sensi-
tivity. Qingdai is a famous TCM herb and is widely used as a therapeutic agent for leukemia in China20,21. The 
published active component in Qingdai was mainly about indirubin. However, clinical and preclinical experi-
ments showed that despite its anti-leukemia effects, its poor solubility in water and severe side-effects limit its 
clinical use22,32. This demonstrated that the satisfactory clinical curative effects of Qingdai might rely on other 
active components. Thus, characterization of the anti-leukemia components in Qingdai and their targets is a big 
task ahead of us.
Using the 2D K562/CMC system, three active components were screened. In this study, the anti-leukemia 
effects of indirubin have also been verified. To be noted, because of its poor water solubility, a large amount of 
this compound would be dissolved out22, so the accurate anti-leukemia results of indirubin could not be achieved 
by cell viability assays in vitro. Since the poor solubility in water and severe side-effects limit the clinical use of 
indirubin, lots of indirubin derivatives with a high efficacy and low toxicity have been developed33,34. If the water 
solubility of indirubin could be improved such as formulation in self-emulsifying drug delivery systems con-
taining E804 (indirubin-3′ -oxime 2,3-dihydroxypropyl ether) and 5-OH-5-nitro-Indirubin oxime (AGM130), 
it would have much better anti-leukemia effects35,36. In a word, indirubin is not a satisfying drug, but it could 
be a good pro-drug. Fortunately, the other two components, tryptanthrin and isorhamnetin, both showed sat-
isfactory anti-leukemia effects, and the results were in accordance with the previous study. Previous research 
reported that tryptanthrin could inhibit cell viability and induce apoptosis in leukemia37 and other cancer cells 
including breast cancer38 and lung cancer39. One of the direct cancer related targets of tryptanthrin was verified 
as cyclooxygenase-240. However, the cancer-related targets of isorhamnetin have been rarely reported before.
Target identification of the known active compounds is an important research field in the modernization of 
TCM. It is also a challenging and costly step towards chemical biology and phenotypic screening41. In silico iden-
tification of potential biological targets for bioactive compounds offers an alternative avenue for the exploration 
of ligand–target interactions and biochemical mechanisms. In silico target screening methods are employed to 
identify the receptors of isorhamnetin. These methods are designed to identify the most probable target of a query 
molecule and different methods are always based on different principles, such as chemical similarity searching, 
data mining/machine learning, panel docking and the bioactivity spectral analysis18. Compared with the exper-
imental methods, it is more efficient, less costly and easier to perform42. What’s more, the complex composition 
of TCM makes it even harder to elucidate the multi-target mode of action between compounds and targets via 
experimental methods. Here, we adopted in silico identification methods and identified Src as a direct receptor 
of isorhamnetin. Previous studies reported that isorhamnetin induced C-terminal Src kinase expression and 
inhibited Src activation in colorectal cancer cells, but it didn’t bind directly to Src43. In this study, various methods 
were adopted to verify the interaction between Src receptor and isorhamnetin. Molecular docking study, CMC 
competitive experiments, SPR analysis and in vitro kinase inhibition assay results all indicated that Src was a 
direct target of isorhamnetin.
www.nature.com/scientificreports/
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Cell growth and proliferation are mediated via cell cycle progression and regulation of the cell cycle has 
become a novel target for the management of cancer. The cell cycle is a critical regulator of the processes of cell 
proliferation and growth after DNA damage44,45. Previous studies45,46 suggested that the anti-leukemia effects 
of isorhamnetin might be through inducing DNA damage. In order to explore the molecular mechanism of 
isorhamnetin via Src, cell cycle analysis was performed and the results showed that isorhamnetin could arrest 
K562 cells at G2/M phase. Western blotting results showed a dose-dependent inhibition of Src416 phosphoryla-
tion by isorhamnetin. Cell cycle related proteins, such as ATR and Wee 1, were up-regulated, while CDK1 and 
cyclinB1 were down-regulated with the presence of isorhamnetin. The CDK1/cyclin B1 complex has been well 
known as the regulators governing the G2 to M phase progression or inducing apoptosis47–49. The results demon-
strated that the cell cycle regulation effects of isorhamnetin were through ATR/Wee 1/Cyclin B1/CDK1 pathways.
To determine if the effects of isorhamnetin on cell cycle regulation were directly through Src receptor, the 
Src receptor was knocked down with siRNA or the phosphorylation state of Src was suppressed by dasatinib. 
Transfection of K562 cells with Src siRNA also reversed the isorhamnetin inhibition of Cyclin B1 and CDK1 
activation seen in cells transfected with the NC siRNA, indicating that activation of the Cyclin B1 and CDK1 
pathways was in part regulated by Src in K562 cells. Then, after the phosphorylation state of Src416 was suppressed 
by dasatinib, the protein levels of Wee 1, Cyclin B1 and CDK1 had no significant difference after treatment with 
isorhamnetin at different concentrations, indicating that the regulation of the Wee 1, Cyclin B1 and CDK1 path-
ways was in part through the phosphorylation of Src416. Taken together, the anti-leukemia effects of isorhamnetin 
were directly through Src by arresting leukemia cells at G2/M and then inducing cell apoptosis.
In conclusion, we have established an integrated strategy of CMC-based active component screening and 
in silico identification to efficiently elucidate the active components and find their potential molecular targets. 
Three active components were successfully screened and Src was verified as a direct target of isorhamnetin, sug-
gesting that isorhamnetin might be a new potent chemopreventive drug candidate or a lead compound for the 
treatment of leukemia. This efficient, practical, and universally applicable strategy might also be used for the iden-
tification of active molecules and their targets in other complex samples besides TCMs, such as drug-containing 
serum, metabolites or mixtures of synthetic compounds.
Methods
Reagents and chemicals. Authentic standards of higher than 99.0% purity were purchased from the fol-
lowing sources: imatinib and dexamethasone, Nanjing Ange Pharmaceutical Co. Ltd. (Nanjing, China); indirubin 
and indigo, Aladdin® (Shanghai, China); dasatinib, Dalian Meilun Biology Technology Co. Ltd (Dalian China); 
Qingdai (collection in Fujian, China) Shanghai Leiyunshang Medicine Corp. (Shanghai, China). Other chemicals 
and reagents: isorhamnetin, Sigma-Aldrich (USA); cell counting kit-8 (CCK-8), Dojindo Molecular Technologies 
(Dojindo Molecular Technologies, Japan); annexin V-FITC apoptosis detection kit, BD PharmingenTM, BD 
Biosciences; RIPA (Radio Immunoprecipitation Assay) lysis buffer, Beyotime Co. (Jiangsu, China). Antibodies 
against Src, pSrc416, cyclin B, ATR, Wee 1 and β -actin, Cell Signaling Technology (USA); DyLightTM 680-labeled 
antibody to rabbit IgG (H+ L), KPL Inc. (Gaithersburg, MD, USA); CDK1, (Abcam laboratories, Cambridge, MA, 
USA). Other reagents were of analytical grade.
Sample preparation. Standard solutions of dexamethasone (10 mM) were prepared in methanol and imati-
nib was prepared in ultrapure water (pH 2.5). Isorhamnetin and dasatinib for cell viability assays were prepared 
in DMSO (20 mM) and diluted to different concentrations with complete RPMI-1640. The end concentration of 
DMSO was < 0.1%. Qingdai (2.5 g) was extracted with 25 ml CHCl3 (with 2% chloral hydrate) for 60 min using 
an ultrasonic extractor. The resulting extract was centrifuged at 12000 × g for 5 min and the supernatant filtered 
through 0.22 μ M nylon filters.
Cell culture. The K562 cell line was obtained from the American Type Culture Collection (Manassas, VA). 
Cells were cultured in RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin and 100 μ g/ml streptomycin 
at 37 °C and in a humidified CO2 (5%) atmosphere.
Construction of the proposed comprehensive 2D K562/CMC system. K562/CMC column 
(10 × 2 mm i.d., 5 μ m) preparation, cell viability assay, and CMC competitive displacement assay were performed 
according to the previously reported method8,9,13. Comprehensive 2D K562/CMC system was constructed accord-
ing to our previously reported method8 with some modifications. K562/CMC column was applied as the first 
dimensional column. Two 500 μ L sampling loops were replaced by two XDB-C18 pre-columns (12.5 × 4.6 mm 
i.d., 5 μ m, Agilent). For the second dimension separation, an XBridgeTM C18 column (100 × 3.0 mm i.d., 3.5 μ m, 
Waters, Ireland) was used and the flow rate was 0.6 mL/min. Chromatographic and mass spectrometer conditions 
are shown in Supplementary methods.
Cell apoptosis assay. The Annexin V-FITC apoptosis detection kit I was used to detect and quantify apop-
tosis by flow cytometry according to the manufacturer’s protocol. In brief, treated and untreated K562 cells were 
prepared as follows: A total of 5 × 105 cells were collected, washed with PBS (10 mM, pH 7.4), and mixed with 
195 μ l of Annexin V-FITC binding buffer and 5 μ l of Annexin V-FITC (under gently mixing in this order). Next, 
10 μ l of propidium iodide (PI) were added to the cells and incubated for 15 min at room temperature in the dark. 
Cell apoptosis was immediately analyzed using BD CellQuest Pro software by FACS Calibur.
Cell cycle assay. K562 cells were harvested and washed with cold PBS (10 mM, pH 7.4) by centrifugation at 
1000 × g for 5 min after the indicated treatments. Then, cells were re-suspended in 70% (v/v) cold ethanol and 
stored at − 20 °C overnight. After incubation at 37 °C with PI solution in the dark for 30 min, cell cycle distribu-
tion was analyzed by BD CellQuest Pro software by FACS Calibur.
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Molecular Docking. The structure of the human Src kinase domain in complex with cancer drug 
bosutinib was obtained from the Protein Data Bank (PDB code 4MXO). Crystal water and bosutinib were 
removed, and hydrogen atoms were added according to the protonation state of chemical groups at pH 7.0. 
The binding site was defined as a 4 Å radius around bosutinib. Isorhamnetin was then docked into the ATP 
binding site of the Src kinase domain using LeDock (http://lephar.com) on the basis of a combination of 
simulated annealing and evolutionary optimization of the ligand pose (position and orientation) and its 
rotatable bonds28.
Kinase inhibition assays. Src kinase inhibition by different compounds was determined using Caliper 
Mobility Shift assays (Caliper Life Sciences, MA) according to the instructions provided29. Staurosporine was 
used as a reference compound.
Western-Blotting. Whole cell protein extraction was conducted according to previous reports with slight 
modifications13. Protein samples (50 μ g) from each lysate were separated by SDS-PAGE and transferred to PVDF 
membranes (0.45 μ m), and blocked with 5% skimmed milk in Tris-buffered saline containing 0.1% Tween-20 
(TBST) at room temperature for 1 h. The membranes were then incubated at 4 °C overnight with primary anti-
bodies against pSrc416 (1:500), Src (1:1000), ATR (1:500), Wee 1 (1:500), CDK1 (1:8000), Cyclin B (1:500) and 
β -Actin (1:1000) and final incubation for 2 h in the dark with DyLightTM 680-labeled rabbit IgG (H+ L) anti-
body. The blots were developed with ECL Western Blotting Substrate (Thermo Fisher Scientific) and analyzed 
by scanning densitometry using a Tanon Image System (Tanon, China). β -Actin was used as an interval control. 
The prepared samples were separated by SDS-PAGE and transferred to PVDF membranes (0.45 μ m). Membranes 
were blocked with 5% skimmed milk and incubated overnight at 4 °C with the primary antibody before addition 
of the secondary antibody (1:1000 dilution) and final incubation for 2 h in the dark. The intensity of bands was 
measured with an Oddysey Fc. detection system (Li-cor).
siRNA transfection. The Src siRNAs were designed and synthesized by GenePharma Co., Ltd (Shanghai, 
China). K562 cells were transiently transfected with siRNA (100 nmol/L) using Lipofectamine 3000 (Life 
Technologies) according to the manufacturer’s instructions. After transfected by siRNA for 48 h, K562 cells were 
collected and then treated by indicated experimental requirements.
Statistical analysis. Statistical analysis was performed with the GraphPad Prism 5.0 software. All data were 
depicted as the mean ± standard deviation of individual values from at least three independent experiments. 
Statistical variation was calculated with the Student’s t-test. Statistical significance was set at p < 0.05.
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